Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy

Abstract

Purpose: The aims of the present study were to examine the effects of intravesical instillation of epirubicin on tumor recurrence and to identify tumors that are at a high risk of recurrence. Methods: Forty-five patients with primary superficial bladder cancer were treated with prophylactic intravesical epirubicin following transurethral resection of the bladder tumor (TUR-BT). Epirubicin (20 mg) was administered intravesically every second week for 4 months and then once a month or every 2 weeks for next 8 months. Patients were analyzed with respect to prognostic factors related to tumor recurrence. Results:The overall recurrence-free rate, calculated using the Kaplan-Meier method, was 76.1 and 52.3% at 2 and 5 years after operation, respectively. These results were better than those reported for patients treated with TUR-BT alone. A univariate analysis demonstrated that high-grade, T1, sessile, large (у 2 cm) and multiple tumors were a significantly high risk for recurrence. A multivariate analysis performed by using the Cox proportional hazard model with stepwise selection showed that morphologic features (pedunculated or sessile) were the most prognostic factors for recurrence. This was followed by age and tumor size. The remaining four factors were not found to contribute significantly to recurrence.Conclusions: Epirubicin appears to be effective in preventing the recurrence of superficial bladder cancer. Morphologic features, patient age and size of the tumor were considered independent risk factors. The risk of recurrence for each tumor should be taken into consideration when the intravesical adjuvant therapy protocol is being selected.

Oncological impact of cystoscopic findings in non‐muscle‐invasive bladder cancer: a meta‐analysis

“…After screening, a full‐text review was performed for 201 articles. According to the inclusion criteria, we finally identified 72 studies comprising 28 139 patients eligible for the meta‐analysis [12–83]. The demographics of each included study are shown in Table 1 and Table S2.…”

“…Of the 72 included studies, five included only Ta NMIBC patients [12–16], and 26 studies included only T1 NMIBC patients [17–42]. The other 41 studies included both Ta and T1 patients [43–83].…”

Identifying Patients with Atrioventricular Septal Defect in Down Syndrome Populations by Using Self-Normalizing Neural Networks and Feature Selection

“…LCA5L (A_16_P03587947) encoding the ligand of LCA5 has been widely reported to participate in centrosomal or ciliary functions according to recent publications [ 76 , 77 ]. Additionally, the interaction between LCA5L and NDK1 has been confirmed to contribute to the pathogenesis of DS with specific CNVs [ 78 , 79 , 80 ]. Although no direct evidence revealed the specific contribution of LCA5L in patients with DS, a study [ 81 ] on the congenital heart defects confirmed that copy number variation of LCA5L also participated in the pathogenesis of congenital heart defects.…”

Cálculo del riesgo biológico de multirrecidiva y progresión del carcinoma urotelial no músculo-invasivo mediante nuevos modelos matemáticos

“…El análisis descriptivo de ambas series revela que el porcentajes de recidiva en ambas centros (48.8% y 56.6%) es similar al de otras series históricas publicadas [10][11][12][13][14][15][16], sin embargo el porcentaje de progresión es menor que en otros estudios [1, 14,[16][17][18] Los factores pronósticos para una primera recidiva son equivalentes al de otras series e incluyen la edad, grado, número y tamaño tumoral junto con el tratamiento. Tanto la presencia de cis como el estadio tumoral, no fueron significativos para la recidiva tumoral [17].…”